The objective is to apply de new vaccine candidate produced by the Finlay Vaccine Institute (IFV, in Spanish) for children with two months or more of hospital or home medical discharge, CEDMED said in a press release.

Thus, CEDMED argued, Soberana Plus candidate may be administered to all Covid-19 convalescent children aged 2, in accordance with Cuba´s present health regulations and provisions.

CEDMED also inspected the facilities sites where clinical trial were conducted, in which it verified compliance with Good Clinical Practices during the application.

Cuba has applied a dose of Soberana Plus since the end of past September for Covid-19 convalescent people aged older than 19, with two months or more of their hospital or home medical discharge.

As many as 9,287,955 people in Cuba (83.0%) have been fully vaccinated with the three national vaccine candidates approved so far by CEDMED (Abdala, Soberana 02 and Soberana Plus).

440,808 people have received a booster, 65 560 of them as part of a clinical study and 375 248 of booster vaccination carried out in selected territories and risk groups (health, tourism workers, among others). mh/pll/mem/znc